Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Tim Clackson"'
Autor:
Zhen Liu, Wilson Guzman, Parker Johnson, Megan McLaughlin, Caitlin O’Toole, Magali Pederzoli-Ribeil, Huawei Qiu, Margaret Karow, Tim Clackson, Jennifer O’Neil, Ugur Eskiocak, Miso Park, Benjamin Nicholson, John C Williams, Kurt A Jenkins, Deborah Moore-Lai, Veronica Flesch, Ronan C O’Hagan, Ulrich Rodeck
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Introduction The clinical benefit of the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab has been well established but limited by immune-related adverse events, especially when ipilimumab is used in combination with anti-PD-(L)1 mAb therapy. To over
Externí odkaz:
https://doaj.org/article/d160ab0121654c39a0d99d2106b97ef4
Autor:
Wilson Guzman, Minjie Zhang, Parker Johnson, Megan McLaughlin, Kurt Jenkins, Hsin-Jung Wu, Hanumantha Rao Madala, Caitlin O’Toole, Magali Pederzoli-Ribeil, Raphael Rozenfeld, Huawei Qiu, Margaret Karow, Tim Clackson, Ronan O’Hagan, Jennifer O’Neil, Ugur Eskiocak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/3724762c0d9f4cefad90ea99d2af8b60
Autor:
Victor M. Rivera, Tim Clackson, Frank Wang, William C. Shakespeare, Narayana I. Narasimhan, Qurish K. Mohemmad, Scott Wardwell, Lauren Moran, Matthew J. Wong, Joseph M. Gozgit
Members of the fibroblast growth factor receptor family of kinases (FGFR1–4) are dysregulated in multiple cancers. Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f39a803ac9fd251dac4bfc2513c8a34
https://doi.org/10.1158/1535-7163.c.6536118
https://doi.org/10.1158/1535-7163.c.6536118
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55a658107edbacb04f85646bc213606
https://doi.org/10.1158/1535-7163.22496250.v1
https://doi.org/10.1158/1535-7163.22496250.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies. Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analogue that selectively targets mTOR and is currently under clinical evaluation. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1569b6d231c9801039f6c0365f86e4e7
https://doi.org/10.1158/1535-7163.c.6535203
https://doi.org/10.1158/1535-7163.c.6535203
Autor:
Victor M. Rivera, Xiaotian Zhu, Kwok-kin Wong, Shengwu Liu, Robert J. Griffin, Johara Chouitar, Michael Fitzgerald, William C. Shakespeare, David Dalgarno, Tim Clackson, Narayana I. Narasimhan, Biplab Das, Stephan G. Zech, Matthew T. Greenfield, Feng Li, Yongbo Hu, Wei-Sheng Huang, Sen Zhang, Yaoyu Ning, Sara Nadworny, Scott D. Wardwell, Shuai Li, Alexandra E. Gould, Theresa E. Baker, Sylvie Vincent, Francois Gonzalvez
Most EGFR exon 20 insertion (EGFRex20ins) driver mutations in non–small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting EGFR-mutated NSCLC, moboc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1233d4a09c246c7e577a052bb61a6464
https://doi.org/10.1158/2159-8290.c.6549370.v1
https://doi.org/10.1158/2159-8290.c.6549370.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31157ac1340d347481ad2e92f31f6667
https://doi.org/10.1158/1535-7163.22496256
https://doi.org/10.1158/1535-7163.22496256
Autor:
Victor M. Rivera, Tim Clackson, Frank Wang, David Clapham, Lauren Moran, Scott D. Wardwell, Michelle Cookson, David Miller, Rachel M. Squillace
Ridaforolimus is a nonprodrug rapamycin analogue that potently inhibits mTOR and has shown significant activity in patients with metastatic sarcoma and endometrial cancer, two diseases where high unmet need remains. Here, we evaluated the activity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19b2a7bd378bf98a50c639945bcc5363
https://doi.org/10.1158/1535-7163.c.6535366
https://doi.org/10.1158/1535-7163.c.6535366
Autor:
Victor M. Rivera, Tim Clackson, Frank Wang, William C. Shakespeare, Narayana I. Narasimhan, Qurish K. Mohemmad, Scott Wardwell, Lauren Moran, Matthew J. Wong, Joseph M. Gozgit
PDF file - 89K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::204d870cea2dd90df5ac2f4c153a4b22
https://doi.org/10.1158/1535-7163.22499316.v1
https://doi.org/10.1158/1535-7163.22499316.v1
Autor:
Victor M. Rivera, Tim Clackson, Frank Wang, David Clapham, Lauren Moran, Scott D. Wardwell, Michelle Cookson, David Miller, Rachel M. Squillace
PDF file - 40K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192df8d186eba84431831e5abd6995f2
https://doi.org/10.1158/1535-7163.22496686
https://doi.org/10.1158/1535-7163.22496686